Developer docs
API playgroundTry for free, no card

Search company profiles

INBRAIN Neuroelectronics

Full company profile

uuid000047x

Namestring
INBRAIN Neuroelectronics
Legal namestring
INBRAIN NEUROELECTRONICS SL
Company typeenum
Private
Founded yearint
2019
Descriptiontext

INBRAIN Neuroelectronics is a Barcelona-based clinical-stage brain-computer interface (BCI) therapeutics company founded in 2019 that develops graphene-based cortical implants to treat neurological disorders. Its core technology replaces conventional metal electrodes with high-resolution, miniaturized graphene arrays capable of both recording neural activity and delivering adaptive stimulation. The company holds an FDA Breakthrough Device Designation for Parkinson's disease and has completed first-in-human clinical trials, with ongoing programs targeting epilepsy, stroke rehabilitation, and speech restoration.

The platform combines the proprietary graphene hardware with on-device and cloud-based AI algorithms that enable closed-loop, real-time adjustment of stimulation parameters based on decoded neural intent and disease-state biomarkers. Strategic partners — Merck KGaA for pharmaceutical-commercialization pathways, Mayo Clinic for US clinical translation, and Microsoft for Azure-integrated agentic AI and time-series LLM decoding — anchor the technology and clinical stack. The company has raised approximately $124M cumulatively, including a $50M Series B in October 2024, and is establishing a US presence via a Boston-area subsidiary.

Commercially, INBRAIN is pre-revenue: there are no marketed products. Future revenue mechanics are expected to follow the implantable Class III neuromodulation model — capital equipment plus per-implant consumables sold to neurosurgery centers and tertiary hospitals — supplemented by potential licensing or co-development income from strategic partners. Go-to-market is being prepared for the US first, leveraging the FDA Breakthrough Designation and Mayo Clinic clinical relationships, with Europe and other major neuromodulation markets likely to follow regulatory clearance.

Short descriptiontext

INBRAIN Neuroelectronics is a Barcelona-based, clinical-stage company developing graphene-based brain-computer interface implants to treat Parkinson's, epilepsy, stroke, and speech disorders. It partners with Merck KGaA, Mayo Clinic, and Microsoft, and holds FDA Breakthrough Device Designation for its Parkinson's program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brain-computer interfaces, graphene neural implants, neuromodulation therapy, BCI therapeutics, implantable neuroelectronics
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Brain-Computer Interface Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Graphene-based BCI Platform Commercialization
TypeHardware Sales
Description

INBRAIN is developing and preparing to commercialize its graphene-based brain-computer interface platform for treating neurological disorders including Parkinson's disease, epilepsy, and stroke rehabilitation. The company has received FDA Breakthrough Device Designation for Parkinson's disease, supporting market entry pathway.

graphene-info.com
2INNERVIA Bioelectronics (Vagus Nerve Therapy)
TypeLicensing Royalties
Description

INBRAIN's subsidiary INNERVIA Bioelectronics develops and commercializes intelligent graphene systems to modulate vagus nerve signals in collaboration with Merck KGaA, targeting inflammatory, metabolic, and endocrine disorders.

inbrain-neuroelectronics.com
3Merck KGaA Development Partnership
TypeLicensing Royalties
Description

Strategic collaboration with Merck KGaA for cardiometabolic treatments development, with Merck signaling commercialization intent around INBRAIN's BCI-Tx platform.

insideprecisionmedicine.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1INNERVIA Bioelectronics
Description

A subsidiary dedicated to the development and commercialization of intelligent graphene systems designed to modulate vagus nerve signals for treating chronic diseases, established in partnership with Merck KGaA

inbrain-neuroelectronics.com
Core offering1 text field

INBRAIN Neuroelectronics develops graphene-based brain-computer interface (BCI) therapeutics for neurological disorders. The end-to-end platform combines skin-like, high-resolution (up to 1024 contacts) bidirectional graphene cortical interfaces with an implantable compact neural processor and AI-powered analytics for real-time closed-loop neural decoding and modulation. Targeted applications include Parkinson's disease, epilepsy, stroke rehabilitation, and speech disorders, with a vagus nerve interface line developed via the INNERVIA Bioelectronics subsidiary in partnership with Merck KGaA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • No device-related adverse events observed in first-in-human trial with 8 patients over 90 days of monitoring
+2 more records
Product overview1 text field

INBRAIN Neuroelectronics is developing a three-vertical product platform based on graphene neural interface technology. The platform consists of a cortical interface (currently in first-in-human studies), an implantable system for Parkinson's disease (FDA Breakthrough Device Designation), and a vagus nerve interface for cardiometabolic applications (via INNERVIA Bioelectronics subsidiary). The core technology combines graphene-based high-resolution neural interfaces (up to 1024 contacts) with an implantable wireless neural processor and AI-powered analytics for real-time closed-loop neural decoding and modulation. INNERVIA Bioelectronics, a subsidiary created with Merck KGaA, focuses on vagus nerve therapies for chronic inflammatory, metabolic, and endocrine disorders.

Product and service5 records
1INBRAIN Graphene Neural Interface Platform (BCI-Tx)
CategoryBrain-Computer Interface Medical Device Platform
Description

End-to-end neural platform combining skin-like, bidirectional, high-resolution (up to 1024 contacts) graphene brain-computer interfaces with an implantable compact neural processor (wireless rechargeable battery) and AI-powered analytics for real-time closed-loop decoding and modulation of brain activity. Designed for therapeutic applications in neurological disorders and as a research/surgical aid.

2BCI-Tx Chip (Rice-sized Bidirectional Graphene BCI)
CategoryImplantable Neuroelectronic Device
Description

Bidirectional graphene brain-computer interface chip that combines graphene neural interfaces with integrated electronics to record and stimulate brain activity in closed loop, using AI-assisted algorithms for real-time parameter adjustment. Targeted for Parkinson's disease, epilepsy, stroke rehabilitation, and speech-decoding applications.

3Parkinson's Disease Implantable System
CategoryTherapeutic Neuroelectronic Implant
Description

Graphene-based implantable neuroelectronic system specifically developed for the treatment of Parkinson's Disease, having received FDA Breakthrough Device Designation. Targets the estimated $400 billion BCI market opportunity for therapeutic applications.

4INNERVIA Bioelectronics (Vagus Nerve Therapy Platform)
CategoryBioelectronic Vagus Nerve Therapy Platform
Description

Subsidiary platform developing intelligent graphene systems designed to modulate vagus nerve signals for treating chronic inflammatory, metabolic, and endocrine disorders. Co-developed with Merck KGaA's Innovation Center under a joint development and commercialization arrangement.

5Graphene Cortical Interface (Surgical / Intraoperative)
CategoryInvestigational Cortical Interface
Description

First-in-human graphene-based cortical interface used during brain tumor resection surgeries to capture high-resolution neural signals and decode speech patterns, with demonstrated favorable safety profile and ability to differentiate healthy from cancerous tissue.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-10
Description

Strategic collaboration to utilize agentic AI powered by Microsoft's Azure AI infrastructure for advancing real-time precision neurology and next-generation brain-computer interface therapeutics. The partnership aims to enable INBRAIN's graphene-based neural platform to continuously learn and adapt to individual patient signals for closed-loop precision interventions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-16
Description

Know-how collaboration agreement with Mayo Clinic to accelerate development and commercialization of graphene-based BCI therapeutics for patients with neurological disorders. Experts from both organizations conduct hands-on evaluation of INBRAIN's investigational BCI-Tx platform in IRB-approved clinical settings.

3ICN2 (Catalan Institute of Nanoscience and Nanotechnology)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-15
Description

INBRAIN is a spin-off from ICN2 and ICREA. The company was founded based on graphene technology research developed at these institutions, and continues collaborative research relationships including the GphT-BCI project.

graphene-info.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-02
Description

Clinical trial sponsor and partner for first-in-human studies of graphene-based cortical interfaces during brain tumor resection surgeries conducted at Manchester Centre for Clinical Neurosciences and Salford Royal Hospital.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2023-01-01
Description

Technology collaboration providing end-to-end digital infrastructure management including Microsoft Azure cloud services, on-premises infrastructure, data science platform development, and laboratory and production-grade environment design. Partnership renewed in 2026 to support Inbrain's transition from R&D to scalable, market-ready operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-08
Description

Joint development agreement with Merck KGaA's Innovation Center to develop next-generation graphene bioelectronic vagus nerve therapies targeting severe chronic diseases. The collaboration created INNERVIA Bioelectronics as a subsidiary of INBRAIN focused on vagus nerve therapies for inflammatory, metabolic, and endocrine disorders. Merck has signaled commercialization intent around INBRAIN's BCI-Tx platform.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INBRAIN Neuroelectronics

Brain-Computer Interface Medical Devicesinbrain-neuroelectronics.com

INBRAIN Neuroelectronics is a Barcelona-based, clinical-stage company developing graphene-based brain-computer interface implants to treat Parkinson's, epilepsy, stroke, and speech disorders. It partners with Merck KGaA, Mayo Clinic, and Microsoft, and holds FDA Breakthrough Device Designation for its Parkinson's program.

What INBRAIN Neuroelectronics does

INBRAIN Neuroelectronics is a Barcelona-based clinical-stage brain-computer interface (BCI) therapeutics company founded in 2019 that develops graphene-based cortical implants to treat neurological disorders. Its core technology replaces conventional metal electrodes with high-resolution, miniaturized graphene arrays capable of both recording neural activity and delivering adaptive stimulation. The company holds an FDA Breakthrough Device Designation for Parkinson's disease and has completed first-in-human clinical trials, with ongoing programs targeting epilepsy, stroke rehabilitation, and speech restoration.

The platform combines the proprietary graphene hardware with on-device and cloud-based AI algorithms that enable closed-loop, real-time adjustment of stimulation parameters based on decoded neural intent and disease-state biomarkers. Strategic partners — Merck KGaA for pharmaceutical-commercialization pathways, Mayo Clinic for US clinical translation, and Microsoft for Azure-integrated agentic AI and time-series LLM decoding — anchor the technology and clinical stack. The company has raised approximately $124M cumulatively, including a $50M Series B in October 2024, and is establishing a US presence via a Boston-area subsidiary.

Commercially, INBRAIN is pre-revenue: there are no marketed products. Future revenue mechanics are expected to follow the implantable Class III neuromodulation model — capital equipment plus per-implant consumables sold to neurosurgery centers and tertiary hospitals — supplemented by potential licensing or co-development income from strategic partners. Go-to-market is being prepared for the US first, leveraging the FDA Breakthrough Designation and Mayo Clinic clinical relationships, with Europe and other major neuromodulation markets likely to follow regulatory clearance.

INBRAIN Neuroelectronics firmographics

Firmographics
Name
INBRAIN Neuroelectronics
Legal name
INBRAIN NEUROELECTRONICS SL
Website
https://inbrain-neuroelectronics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
INBRAIN Neuroelectronics is a Barcelona-based, clinical-stage company developing graphene-based brain-computer interface implants to treat Parkinson's, epilepsy, stroke, and speech disorders. It partners with Merck KGaA, Mayo Clinic, and Microsoft, and holds FDA Breakthrough Device Designation for its Parkinson's program.
Ownership category
akta.pro rank

INBRAIN Neuroelectronics industry classification

Industry
Product category
Brain-Computer Interface Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Brain-computer interfaces
  • Graphene neural implants
  • Neuromodulation therapy
  • BCI therapeutics
  • Implantable neuroelectronics

Where INBRAIN Neuroelectronics is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices3 records

Markets served

INBRAIN Neuroelectronics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Graphene-based BCI Platform Commercialization: INBRAIN is developing and preparing to commercialize its graphene-based brain-computer interface platform for treating neurological disorders including Parkinson's disease, epilepsy, and stroke rehabilitation. The company has received FDA Breakthrough Device Designation for Parkinson's disease, supporting market entry pathway.
  2. INNERVIA Bioelectronics (Vagus Nerve Therapy): INBRAIN's subsidiary INNERVIA Bioelectronics develops and commercializes intelligent graphene systems to modulate vagus nerve signals in collaboration with Merck KGaA, targeting inflammatory, metabolic, and endocrine disorders.
  3. Merck KGaA Development Partnership: Strategic collaboration with Merck KGaA for cardiometabolic treatments development, with Merck signaling commercialization intent around INBRAIN's BCI-Tx platform.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

INBRAIN Neuroelectronics product offering

Product offering

Core offering

INBRAIN Neuroelectronics develops graphene-based brain-computer interface (BCI) therapeutics for neurological disorders. The end-to-end platform combines skin-like, high-resolution (up to 1024 contacts) bidirectional graphene cortical interfaces with an implantable compact neural processor and AI-powered analytics for real-time closed-loop neural decoding and modulation. Targeted applications include Parkinson's disease, epilepsy, stroke rehabilitation, and speech disorders, with a vagus nerve interface line developed via the INNERVIA Bioelectronics subsidiary in partnership with Merck KGaA.

Product overview

INBRAIN Neuroelectronics is developing a three-vertical product platform based on graphene neural interface technology. The platform consists of a cortical interface (currently in first-in-human studies), an implantable system for Parkinson's disease (FDA Breakthrough Device Designation), and a vagus nerve interface for cardiometabolic applications (via INNERVIA Bioelectronics subsidiary). The core technology combines graphene-based high-resolution neural interfaces (up to 1024 contacts) with an implantable wireless neural processor and AI-powered analytics for real-time closed-loop neural decoding and modulation. INNERVIA Bioelectronics, a subsidiary created with Merck KGaA, focuses on vagus nerve therapies for chronic inflammatory, metabolic, and endocrine disorders.

Differentiator

Problem solved

Functional benefit

Brands

  • INNERVIA Bioelectronics: A subsidiary dedicated to the development and commercialization of intelligent graphene systems designed to modulate vagus nerve signals for treating chronic diseases, established in partnership with Merck KGaA

Products and services

  • INBRAIN Graphene Neural Interface Platform (BCI-Tx) End-to-end neural platform combining skin-like, bidirectional, high-resolution (up to 1024 contacts) graphene brain-computer interfaces with an implantable compact neural processor (wireless rechargeable battery) and AI-powered analytics for real-time closed-loop decoding and modulation of brain activity. Designed for therapeutic applications in neurological disorders and as a research/surgical aid.
  • BCI-Tx Chip (Rice-sized Bidirectional Graphene BCI) Bidirectional graphene brain-computer interface chip that combines graphene neural interfaces with integrated electronics to record and stimulate brain activity in closed loop, using AI-assisted algorithms for real-time parameter adjustment. Targeted for Parkinson's disease, epilepsy, stroke rehabilitation, and speech-decoding applications.
  • Parkinson's Disease Implantable System Graphene-based implantable neuroelectronic system specifically developed for the treatment of Parkinson's Disease, having received FDA Breakthrough Device Designation. Targets the estimated $400 billion BCI market opportunity for therapeutic applications.
  • INNERVIA Bioelectronics (Vagus Nerve Therapy Platform) Subsidiary platform developing intelligent graphene systems designed to modulate vagus nerve signals for treating chronic inflammatory, metabolic, and endocrine disorders. Co-developed with Merck KGaA's Innovation Center under a joint development and commercialization arrangement.
  • Graphene Cortical Interface (Surgical / Intraoperative) First-in-human graphene-based cortical interface used during brain tumor resection surgeries to capture high-resolution neural signals and decode speech patterns, with demonstrated favorable safety profile and ability to differentiate healthy from cancerous tissue.

Quantifiable outcome

  • No device-related adverse events observed in first-in-human trial with 8 patients over 90 days of monitoring
  • +2 more outcomes

Companies that use INBRAIN Neuroelectronics

Customer profile

Segments3 records

Ideal customer profiles2 records

INBRAIN Neuroelectronics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

INBRAIN Neuroelectronics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • MicrosoftcoreTechnology or Integration · 10 November 2025Strategic collaboration to utilize agentic AI powered by Microsoft's Azure AI infrastructure for advancing real-time precision neurology and next-generation brain-computer interface therapeutics. The partnership aims to enable INBRAIN's graphene-based neural platform to continuously learn and adapt to individual patient signals for closed-loop precision interventions.
  • Mayo CliniccoreStrategic or Co-development Partner · 16 September 2025Know-how collaboration agreement with Mayo Clinic to accelerate development and commercialization of graphene-based BCI therapeutics for patients with neurological disorders. Experts from both organizations conduct hands-on evaluation of INBRAIN's investigational BCI-Tx platform in IRB-approved clinical settings.
  • ICN2 (Catalan Institute of Nanoscience and Nanotechnology)coreStrategic or Co-development Partner · 15 September 2025INBRAIN is a spin-off from ICN2 and ICREA. The company was founded based on graphene technology research developed at these institutions, and continues collaborative research relationships including the GphT-BCI project.
  • University of Manchester / Northern Care Alliance NHS Foundation TrustcoreStrategic or Co-development Partner · 2 October 2024Clinical trial sponsor and partner for first-in-human studies of graphene-based cortical interfaces during brain tumor resection surgeries conducted at Manchester Centre for Clinical Neurosciences and Salford Royal Hospital.
  • KyndrylsupportingTechnology or Integration · 1 January 2023Technology collaboration providing end-to-end digital infrastructure management including Microsoft Azure cloud services, on-premises infrastructure, data science platform development, and laboratory and production-grade environment design. Partnership renewed in 2026 to support Inbrain's transition from R&D to scalable, market-ready operations.
  • Merck KGaAcoreStrategic or Co-development Partner · 8 July 2021Joint development agreement with Merck KGaA's Innovation Center to develop next-generation graphene bioelectronic vagus nerve therapies targeting severe chronic diseases. The collaboration created INNERVIA Bioelectronics as a subsidiary of INBRAIN focused on vagus nerve therapies for inflammatory, metabolic, and endocrine disorders. Merck has signaled commercialization intent around INBRAIN's BCI-Tx platform.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

INBRAIN Neuroelectronics competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

INBRAIN Neuroelectronics social profiles

Digital presence

INBRAIN Neuroelectronics compliance and trust

Trust signal

Compliance1 record

INBRAIN Neuroelectronics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INBRAIN Neuroelectronics leadership team

Management profile

Number of profiles

Profiles18 records

INBRAIN Neuroelectronics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

INBRAIN Neuroelectronics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INBRAIN Neuroelectronics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INBRAIN Neuroelectronics

What does INBRAIN Neuroelectronics do?

INBRAIN Neuroelectronics develops graphene-based brain-computer interface (BCI) therapeutics for neurological disorders. The end-to-end platform combines skin-like, high-resolution (up to 1024 contacts) bidirectional graphene cortical interfaces with an implantable compact neural processor and AI-powered analytics for real-time closed-loop neural decoding and modulation. Targeted applications include Parkinson's disease, epilepsy, stroke rehabilitation, and speech disorders, with a vagus nerve interface line developed via the INNERVIA Bioelectronics subsidiary in partnership with Merck KGaA.

Is INBRAIN Neuroelectronics a public or private company?

INBRAIN Neuroelectronics is a private company. It is classified as venture growth investor backed and is currently operating.

When was INBRAIN Neuroelectronics founded?

INBRAIN Neuroelectronics was founded in 2019. It employs 101 to 250 people.

Where is INBRAIN Neuroelectronics based?

INBRAIN Neuroelectronics is headquartered in Barcelona, Spain, in the Europe region.

How does INBRAIN Neuroelectronics make money?

Three revenue lines are on record. Graphene-based BCI Platform Commercialization is the primary driver. The others are INNERVIA Bioelectronics (Vagus Nerve Therapy) and merck KGaA Development Partnership.

Does INBRAIN Neuroelectronics have an API?

No public API is recorded for INBRAIN Neuroelectronics.

What industry is INBRAIN Neuroelectronics in?

INBRAIN Neuroelectronics's product category is Brain-Computer Interface Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyEuropean consortium creates ultra-thin brain implant for Parkinson’s treatmentThe MINIGRAPH consortium, funded by the European Innovation Council, developed ultra-thin graphene neural interfaces and a magnetically guided robotic implantation procedure for Parkinson's treatment. The project includes INBRAIN, ICN2, imec, and others, with accelerated ageing tests projecting over 10 years of stability. A functionally validated prototype was created to enable future autonomous neuroelectronic therapies.Medical Device NetworkINBRAIN reports data from MINIGRAPH project for brain disordersINBRAIN Neuroelectronics reported outcomes from the MINIGRAPH project, which combined graphene probes with implantable microelectronics and a surgical delivery system for deep brain stimulation. The project, funded by the European Innovation Council, targeted Parkinson's disease and validated a prototype in a large animal model. The consortium includes ETH Zurich, Nanoflex Robotics, and others.WebProNewsInbrain Neuroelectronics Unveils Minigraph for Minimally Invasive Brain Implant DeliveryInbrain Neuroelectronics unveiled Minigraph, a magnetic robot that delivers graphene-based brain implants via a small burr hole. The device uses external magnetic fields to guide ultra-thin electrodes, reducing trauma and enabling high-resolution recording and stimulation. Human trials are expected within two years, pending regulatory approvals.Business Wire BlogINBRAIN Neuroelectronics and MINIGRAPH European Consortium Develop Magnetically Guided Robotic Implantation for Ultra-Thin Graphene Brain-Computer InterfacesINBRAIN Neuroelectronics and a European consortium completed the MINIGRAPH project, developing ultra-thin graphene neural interfaces and a magnetic-robotic implantation procedure. The system was validated in preclinical models and aims to enable scalable, autonomous brain-computer interfaces for disorders like Parkinson's disease.FinancialContent Business PageINBRAIN Neuroelectronics and MINIGRAPH European Consortium Develop Magnetically Guided Robotic Implantation for Ultra-Thin Graphene Brain-Computer InterfacesINBRAIN Neuroelectronics and the MINIGRAPH consortium completed a European project developing graphene-based brain-computer interfaces with robotic implantation. The system uses magnetic navigation for precise, minimally invasive placement of ultra-thin neural probes, validated in animal models. The goal is to enable scalable, autonomous neurotherapeutics for conditions like Parkinson's disease.Empresas de Capital Riesgo en EspaBStartup Health launches its ninth call for applicationsBStartup Health is opening its ninth call for pre-seed and seed-stage healthcare startups, with applications due July 19. The programme highlights a €100 million financing round by INBRAIN Neuroelectronics, a portfolio company. The call targets Medical Devices, Diagnostics, Therapeutics & Drugs, and eHealth.InsideprecisionmedicineCarolina Aguilar: Brain-Computer Interfaces that Heal Neural CircuitsINBRAIN Neuroelectronics, a graphene-based brain-computer interface company founded by former Medtronic executive Carolina Aguilar, is developing therapeutic BCI systems targeting neurological and cardiometabolic diseases. The company has completed first-in-human trials of its short-term cortical interface, demonstrating safety and superior neural decoding compared to traditional metal-based devices. INBRAIN is pursuing a three-vertical product strategy—a temporary cortical interface, an implantable platform for Parkinson's disease, and a vagus nerve interface—positioned within a reported $400 billion BCI market opportunity, while also engaging in undisclosed cardiometabolic development work with Merck KGaA.Interesting EngineeringFirst-in-human study confirms safety of graphene-based brain interfaceINBRAIN Neuroelectronics conducted a first-in-human study involving a graphene-based cortical interface, recruiting ten patients, with eight undergoing surgery using the device. The device performed well with no safety issues, and the study demonstrated its ability to capture high-resolution neural signals safely during brain tumor surgeries. The company plans to expand the technology for broader neurological treatments and is moving toward commercialization.Medical Device NetworkINBRAIN concludes enrolment for graphene neural interface trialSpanish neurotechnology company INBRAIN Neuroelectronics has concluded patient enrolment for its first-in-human study of a graphene neural interface, recruiting 10 patients (8 surgically treated) undergoing brain tumour resection surgery with no perioperative device failures or device-related adverse events reported. The study, sponsored by the University of Manchester and conducted with Northern Care Alliance NHS Foundation Trust, found a favourable safety profile for the graphene-based cortical interface while testing signal quality, interface stability, and compatibility with existing surgical systems. The company plans to announce full results this year as it advances toward commercialisation, having previously partnered with Microsoft in November 2025.BioSpaceINBRAIN Neuroelectronics Completes Enrolment of World’s First-in-Human Study of Graphene Neural Interfaces for Brain Decoding & MappingINBRAIN Neuroelectronics announced the completion of patient recruitment for its first-in-human study evaluating graphene-based cortical interfaces in ten patients. The study, conducted by the University of Manchester and Northern Care Alliance NHS Foundation Trust, demonstrated a favorable safety profile with no device-related adverse events or failures during neurosurgical procedures. High-resolution neural signal capture was achieved, supporting the potential for next-generation brain-computer interface therapeutics.